Patents by Inventor Ulrich Griesser

Ulrich Griesser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200062750
    Abstract: The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia.
    Type: Application
    Filed: February 1, 2018
    Publication date: February 27, 2020
    Applicant: Sandoz AG
    Inventors: Christoph Langes, Ulrich Griesser, Erwin Schreiner, Marijan Stefinovic
  • Patent number: 10323056
    Abstract: The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: June 18, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Lovro Selic, Andreas Hotter, Christoph Langes, Ulrich Griesser
  • Patent number: 9534004
    Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 3, 2017
    Assignee: SANDOZ AG
    Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
  • Patent number: 9499504
    Abstract: The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with characteristic peaks (expressed in 2?±0.2° 2? (CuK? radiation)) at 5.5°, 14.8°, 16.7° and 20.0° and processes for obtaining the same.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: November 22, 2016
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Michael Enders, Ulrich Griesser
  • Patent number: 9440924
    Abstract: The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: September 13, 2016
    Assignee: SANDOZ AG
    Inventors: Josef Wieser, Ulrich Griesser, Michael Enders, Volker Kahlenberg
  • Publication number: 20160200750
    Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 14, 2016
    Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
  • Publication number: 20160145286
    Abstract: The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.
    Type: Application
    Filed: May 7, 2014
    Publication date: May 26, 2016
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Lovro Selic, Andreas Hotter, Christoph Langes, Ulrich Griesser
  • Patent number: 9266868
    Abstract: Provided are a crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions containing the crystalline dihydrate and processes for preparing and storing the pharmaceutical compositions. Also provided are a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and the use of the Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: February 23, 2016
    Assignee: SANDOZ AG
    Inventors: Johannes Ludescher, Hubert Sturm, Ulrich Griesser, Robert E. Ziegert-Knepper, Arthur Pichler, Mairi Haddow
  • Publication number: 20160039871
    Abstract: The invention relates to an amorphous form of telaprevir, its preparation via novel crystalline Form C of telaprevir (also referred to as “crystalline Form C” or “Form C”), and telaprevir compositions comprising said amorphous form and Form C. Furthermore, the present invention relates to the use of said amorphous telaprevir, telaprevir composition and Form C of telaprevir for the preparation of medicaments such as anti-hepatitis C medicaments. Moreover, the present invention relates to pharmaceutical compositions and dosage forms comprising a pharmaceutically effective amount of said novel forms for use in treating patients suffering from hepatitis C virus.
    Type: Application
    Filed: December 20, 2013
    Publication date: February 11, 2016
    Inventors: Marijan Stefinovic, Christoph Langes, Ulrich Griesser
  • Publication number: 20150266841
    Abstract: The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2[2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with characteristic peaks (expressed in 2?±0.2° 2? (CuK? radiation)) at 5.5°, 14.8°, 16.7° and 20.0° and processes for obtaining the same.
    Type: Application
    Filed: September 18, 2013
    Publication date: September 24, 2015
    Applicant: SANDOZ AG
    Inventors: Andreas Hotter, Michael Enders, Ulrich Griesser
  • Patent number: 8946441
    Abstract: The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: February 3, 2015
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Ulrich Griesser, Verena Adamer, Christoph Langes
  • Publication number: 20140336179
    Abstract: The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride.
    Type: Application
    Filed: July 31, 2012
    Publication date: November 13, 2014
    Applicant: SANDOZ AG
    Inventors: Josef Wieser, Ulrich Griesser, Michael Enders, Volker Kahlenberg
  • Patent number: 8563555
    Abstract: The present invention relates to a pharmaceutical composition comprising crystalline form Y of posaconazole. The pharmaceutical composition can be used to treat or prevent fungal infections.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: October 22, 2013
    Assignee: Sandoz AG
    Inventors: Josef Wieser, Arthur Pichler, Andreas Hotter, Ulrich Griesser, Christoph Langes, Christian Laschober
  • Publication number: 20130245017
    Abstract: The present invention relates to a novel crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline dehydrate and to processes for preparing and storing said pharmaceutical compositions. The invention also relates to a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and to the use of said Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.
    Type: Application
    Filed: July 5, 2011
    Publication date: September 19, 2013
    Applicant: SANDOZ AG
    Inventors: Johannes Ludescher, Hubert Sturm, Ulrich Griesser, Robert E. Ziegert-Knepper, Arthur Pichler, Mairl Haddow
  • Publication number: 20130137734
    Abstract: The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions camprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 30, 2013
    Applicant: SANDOZ AG
    Inventors: Andreas Hotter, Ulrich Griesser, Verena Adamer, Christoph Langes
  • Patent number: 8435998
    Abstract: The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: May 7, 2013
    Assignee: Sandoz AG
    Inventors: Josef Wieser, Arthur Pichler, Andreas Hotter, Ulrich Griesser, Christoph Langes
  • Patent number: 8309769
    Abstract: The present invention relates to two crystalline forms of 2-[2-chloro-4-methylsulfonyl-3-(2,2,2-trifluoro-ethoxymethyl)benzoyl]cyclohexan-1,3-dione, which is also known under the common name tembotrione. The invention also relates to a process for the production of these crystalline forms and formulations for plant protection which contain one of these crystalline forms of tembotrione.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: November 13, 2012
    Assignee: BASF SE
    Inventors: Eike Hupe, Markus Gewehr, Peter Erk, Heidi Emilia Saxell, Ulrich Griesser, Michaela Tischler
  • Patent number: 8222380
    Abstract: The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: July 17, 2012
    Assignee: Sandoz AG
    Inventors: Johannes Ludescher, Ulrich Griesser, Christoph Langes
  • Publication number: 20120101277
    Abstract: The present invention relates to crystalline form II-S, its preparation and its use to prepare other crystalline forms of posaconazole, in particular crystalline form IV of posaconazole.
    Type: Application
    Filed: July 9, 2010
    Publication date: April 26, 2012
    Applicant: SANDOZ AG
    Inventors: Josef Wieser, Arthur Pichler, Andreas Hotter, Ulrich Griesser, Christoph Langes
  • Patent number: 8008490
    Abstract: The present invention relates to novel polymorphic forms of aripiprazole and processes for producing them. It further relates to pharmaceutical compositions comprising the novel forms and to the use of the novel forms in the treatment of schizophrenia.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: August 30, 2011
    Assignee: Sandoz AG
    Inventors: Josef Wieser, Hannes Lengauer, Doris Braun, Ulrich Griesser, Richard Tessadri